Skip to main content
Welcome to
super saver spring
offer ends april 20
save over $140
save over 85%
$0.99
per week for 24 weeks
Welcome to
super saver spring
$0.99
per week
for 24 weeks
// //

A nurse fills a syringe with a dose of AstraZeneca's COVID-19 vaccine at a health care centre in Seoul, on Feb. 26, 2021.

Jung Yeon-je/The Associated Press

South Korean authorities are investigating the deaths of two people, both with pre-existing conditions, who died within days of receiving AstraZeneca’s COVID-19 vaccine.

AstraZeneca said it was aware of the investigation by the Korea Disease Control and Prevention Agency (KDCA), but the safety of the vaccine has been extensively studied in clinical trials with data confirming it is generally well tolerated.

“KDCA is conducting epidemiological surveys with relevant local authorities … to confirm any link with inoculation,” KDCA Director Jeong Eun-kyeong told a briefing.

Story continues below advertisement

But it did not yet confirm any causal relationship to the vaccine.

A 63-year-old nursing home patient with cerebrovascular disease, developed symptoms including high fever, after being given the vaccine four days ago, Jeong said.

The man was moved to a larger hospital on Tuesday, but died after showing symptoms of blood poisoning and pneumonia, Yonhap news agency reported.

Another nursing home patient in his 50s with a cardiac disorder and diabetes died on Wednesday after suffering multiple heart attacks, having received the vaccine a day earlier, the agency said.

Jeong said there were no cases of fatalities from receiving COVID-19 vaccines developed by AstraZeneca or Pfizer/BioNTech. However, did urge people to take the shot when they are feeling in good health.

The KDCA said that out of the people who had received the coronavirus vaccines, 207 had adverse reactions, including three cases of severe allergic reactions, known as anaphylaxis.

South Korea began vaccinating its population last week. By Tuesday midnight, 85,904 people had received the first doses of the AstraZeneca vaccine and 1,524 had been given Pfizer shots, KDCA said in a statement.

Story continues below advertisement

South Korea reported 444 new confirmed COVID-19 cases on Tuesday, up from 344 on Monday, raising the country’s tally to 90,816 infections, with 1,612 deaths.

The agency earlier said it would provide compensation of over 430 million won ($383,500) for deaths from the COVID-19 vaccine.

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies